Lymphoma, T-Cell, Peripheral Clinical Trial
Official title:
Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.
In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in PTCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03547700 -
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
|
Phase 1/Phase 2 | |
| Completed |
NCT02788916 -
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
|
N/A | |
| Completed |
NCT02567656 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01142674 -
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
|
||
| Withdrawn |
NCT03355768 -
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
|
Phase 3 | |
| Not yet recruiting |
NCT05006664 -
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
|
Phase 2 | |
| Terminated |
NCT00514722 -
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
|
N/A | |
| Completed |
NCT01679860 -
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06254495 -
A Safety Study of SGN-35C in Adults With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT05137847 -
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
|
||
| Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
| Completed |
NCT03049449 -
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
|
Phase 1 | |
| Completed |
NCT00211185 -
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT03051581 -
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
|
N/A | |
| Completed |
NCT00646854 -
Alemtuzumab and CHOP in T-cell Lymphoma
|
Phase 3 | |
| Terminated |
NCT02535247 -
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02364466 -
Cohort of Peripheral T Cell Lymphoma
|
N/A | |
| Recruiting |
NCT02404571 -
GDP in Frontline Chemotherapy for Patients With PTCL-NOS
|
Phase 2 | |
| Completed |
NCT03742921 -
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
|
||
| Completed |
NCT02181218 -
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
|
Phase 1 |